ARA-290

ARA-290, also known as Cibinetide, is a synthetic peptide designed to target a specific receptor in the body called the innate repair receptor. Unlike erythropoietin (EPO), which acts on the same family of receptors but primarily affects red blood cell counts, ARA-290 is engineered to access only the tissue-protective side of that receptor - providing anti-inflammatory and neuroprotective benefits without altering blood counts. How it works: ARA-290 activates the innate repair receptor to reduce neuropathic pain and inflammation. This receptor plays a role in tissue healing and nerve protection, and activating it helps calm the inflammatory environment around damaged nerves and tissues. Who tends to use it: ARA-290 is most commonly considered by people dealing with nerve-related pain - small-fiber neuropathy in particular is an area where it has been studied - as well as those seeking general recovery support or immune modulation. Its goal weights sit primarily at recovery and secondarily at immune support and longevity. What to expect: ARA-290 is not a fast-acting analgesic. It works over a course of weeks, supporting tissue and nerve recovery through an anti-inflammatory mechanism rather than blocking pain signals directly. How it is taken: ARA-290 is given by subcutaneous injection, in a dose range of 1-4 mg, once daily. Timing within the day is flexible. Protocols typically run 4-12 weeks. Safety notes: ARA-290 is described as well tolerated in the context of small-fiber neuropathy use. There are no exclusion flags for pregnancy or cancer history. It is an investigational compound without FDA approval. It pairs with BPC-157 in recovery-focused protocols. Your specific dose, timing, and protocol length are set in consultation with a licensed provider in the PepDepo network.